Medicus Pharma Ltd (MDCX) Stock Price, Quote & News

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus P...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 610 636 0184

Website: medicuspharma.com

Address:

300 Conshohocken State Road, Suite 200, West Conshohocken, United States

calderinho Jun. 12 at 11:12 AM

$MDCX

0 · Reply

stocks_2watch Jun. 11 at 5:51 PM

$MDCX, Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix®️ in Endometriosis utilizing the Emirati Genome Program: https://medicuspharma.com/medicus-pharma-initiates-groundbreaking-precision-e2-phase-2a-study-of-teverelix-in-endometriosis-utilizing-the-emirati-genome-program/

0 · Reply

DARKP00L Jun. 11 at 12:14 PM

$MDCX 07:34 on Jun. 11 2026 Medicus Pharma Submits IND Application To DOH For PRECISION-E2, Phase 2a Genomics-Enabled Clinical Trial Evaluating Teverelix In Women With Symptomatic Endometriosis In UAE #tradeideas

0 · Reply

focafoca99 Jun. 11 at 11:56 AM

$MDCX commenced a Phase 2a precision trial of Teverelix for endometriosis in the UAE.

0 · Reply

SuperGreenToday Jun. 11 at 1:43 AM

$MDCX

0 · Reply

Moneyindabanknow Jun. 10 at 5:07 PM

$MDCX This is gonna move big to upside when you least expect it. Will not be able to catch. Will you be in and holding?

0 · Reply

kubertradespennies Jun. 10 at 4:10 PM

$MDCX what is up with the low volume ?

1 · Reply

NVDAMillionaire Jun. 10 at 1:05 PM

$MDCX Brilliant piece that captures MDCX's situation perfectly. So if you want to update your understanding of MDCX or get to know MDCX better, this is essential reading. https://everyticker.com/quote/MDCX/analysis/mdcx-a-17-million-bet-on-two-shots-at-8-billion-markets-with-a-two-month-fuse

0 · Reply

Makomemoney Jun. 9 at 12:31 PM

$MDCX FDA approval for ODD is imminent. Only a matter of what day it will drop.

0 · Reply

Sum_guy_69 Jun. 9 at 3:41 AM

$MDCX 👍

0 · Reply

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

UAE

2026-06-08T11:37:41.000Z - 4 days ago

Medicus Pharma submits substantial modification application through EU CTIS

Jun 8, 2026, 7:30 AM EDT - 4 days ago

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

2026-06-03T13:37:23.000Z - 9 days ago

Medicus Pharma submits Protocol SKNJCT-005 to the FDA

Jun 3, 2026, 8:00 AM EDT - 9 days ago

Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome

May 28, 2026, 8:00 AM EDT - 15 days ago

Medicus Pharma Announces $22 Million Non-Dilutive Financing

2026-05-14T22:18:41.000Z - 4 weeks ago

Medicus Pharma reports Q1 EPS (31c), consensus (22c)

May 14, 2026, 4:30 PM EDT - 4 weeks ago

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-05-07T03:48:38.000Z - 5 weeks ago

Medicus Pharma announces results from Phase 2 SKNJCT-003 analysis

May 6, 2026, 7:30 AM EDT - 5 weeks ago

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

2026-04-27T13:31:02.000Z - 6 weeks ago

Medicus Pharma meets with lawmakers to support SkinJect designations

Apr 27, 2026, 7:30 AM EDT - 6 weeks ago

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

2026-04-21T11:53:55.000Z - 7 weeks ago

Medicus Pharma initiated with a Buy at Roth Capital

2026-04-17T11:35:50.000Z - 2 months ago

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

Apr 17, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Apr 15, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

2026-04-07T14:23:02.000Z - 2 months ago

Medicus Pharma enters media partnership with New to The Street

2026-04-06T11:37:11.000Z - 2 months ago

Medicus Pharma submits clinical study design to FDA for Teverelix

Apr 6, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention

Apr 1, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

2026-03-30T13:38:08.000Z - 2 months ago

Medicus Pharma reports principal investigator validation of Phase 2 data

Mar 30, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Mar 26, 2026, 7:30 AM EDT - 2 months ago

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Mar 25, 2026, 4:30 PM EDT - 2 months ago

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

2026-03-18T11:52:25.000Z - 3 months ago

Medicus Pharma to discuss Skinject Phase 2 reults in fireside chat

Mar 18, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

2026-03-16T11:50:31.000Z - 3 months ago

Medicus Pharma announces SkinJect Phase 2 KOL update

Mar 16, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Mar 10, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

2026-03-09T11:40:33.000Z - 3 months ago

Medicus Pharma provides interpretation of Phase 2 SkinJect dataset

Mar 9, 2026, 7:30 AM EDT - 3 months ago

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

2026-03-05T13:10:22.000Z - 3 months ago

Medicus Pharma announces results from Phase 2 study of D-MNA

2026-03-05T12:35:46.000Z - 3 months ago

Medicus Pharma announces results from Phase 2 study of D-MNA

Mar 5, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Mar 3, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma To Participate in the 38th Annual Roth Conference

Feb 12, 2026, 7:30 AM EST - 4 months ago

Medicus Pharma on Bloomberg World

2026-02-10T13:40:50.000Z - 4 months ago

Medicus signs six-part media series with New to the Street

2026-02-10T12:35:27.000Z - 4 months ago

Medicus receives FDA ‘study may proceed’ clearance for Teverelix Phase 2b study

Feb 10, 2026, 7:30 AM EST - 4 months ago

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Jan 23, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

2026-01-22T12:35:45.000Z - 5 months ago

Medicus announces amendment to LifeArc license improving Teverelix profile

Jan 22, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Jan 20, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

2026-01-12T12:50:08.000Z - 5 months ago

Medicus Pharma announces clinical data on Teverelix

Jan 12, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Jan 5, 2026, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

2025-12-22T12:46:17.000Z - 6 months ago

Medicus Pharma enters non-binding LOI with Reliant AI

Dec 22, 2025, 7:30 AM EST - 6 months ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Dec 15, 2025, 7:30 AM EST - 6 months ago

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Dec 5, 2025, 3:20 PM EST - 6 months ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 1, 2025, 8:00 AM EST - 6 months ago

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Nov 24, 2025, 8:00 AM EST - 7 months ago

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Nov 17, 2025, 7:30 AM EST - 7 months ago

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 14, 2025, 5:00 PM EST - 7 months ago

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 13, 2025, 7:30 AM EST - 7 months ago

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 29, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Oct 22, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 14, 2025, 8:07 AM EDT - 8 months ago

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 13, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 7, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Sep 29, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 24, 2025, 9:26 AM EDT - 9 months ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 18, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Sep 8, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Sep 2, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Aug 21, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Aug 4, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Jul 23, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

calderinho Jun. 12 at 11:12 AM

$MDCX

0 · Reply

stocks_2watch Jun. 11 at 5:51 PM

0 · Reply

DARKP00L Jun. 11 at 12:14 PM

0 · Reply

focafoca99 Jun. 11 at 11:56 AM

$MDCX commenced a Phase 2a precision trial of Teverelix for endometriosis in the UAE.

0 · Reply

SuperGreenToday Jun. 11 at 1:43 AM

$MDCX

0 · Reply

Moneyindabanknow Jun. 10 at 5:07 PM

$MDCX This is gonna move big to upside when you least expect it. Will not be able to catch. Will you be in and holding?

0 · Reply

kubertradespennies Jun. 10 at 4:10 PM

$MDCX what is up with the low volume ?

1 · Reply

NVDAMillionaire Jun. 10 at 1:05 PM

0 · Reply

Makomemoney Jun. 9 at 12:31 PM

$MDCX FDA approval for ODD is imminent. Only a matter of what day it will drop.

0 · Reply

Sum_guy_69 Jun. 9 at 3:41 AM

$MDCX 👍

0 · Reply

woodruffn2 Jun. 8 at 4:13 PM

$MDCX do something

1 · Reply

stocks_2watch Jun. 8 at 3:17 PM

$MDCX, Medicus Pharma Advances Teverelix®️ Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission: https://medicuspharma.com/medicus-pharma-advances-teverelix-program-towards-registrational-development-targeting-high-cardiovascular-risk-prostate-cancer-patients-with-key-european-submission/

0 · Reply

DARKP00L Jun. 8 at 1:26 PM

$MDCX 07:35 on Jun. 08 2026 Medicus Pharma Submits Modification Application Through European Union Clinical Trials Information System For Its Phase 2b Trial Of Teverelix In Advanced Prostate Cancer #tradeideas

0 · Reply

dzetu Jun. 5 at 2:47 PM

$MDCX Increased my position again by 34k shares. Still optimistic, I see great potential. This is my second-largest holding after $CAPR.

3 · Reply

Krystalp9885 Jun. 5 at 2:25 PM

$MDCX

0 · Reply

ZTRADEZ_LLC Jun. 5 at 1:41 PM

(NASDAQ: $MDCX )*Medicus Pharma Ltd (ON MY RADAR) MDCX is a clinical stage biotechnology company developing needle free treatments for skin cancer and other dermatology related conditions. Technical - Resting on a volume shelf and showing signs of a reversal. - Low-volume area ahead between $0.41 and $0.57. - Float sits below 10M shares. Fundamental • Advanced SkinJect into registrational development for Gorlin Syndrome, a rare genetic disorder associated with recurring skin cancers. • Secred up to $22 million in non dilutive financing to support clinical and regulatory milestones. • Phase 2 data demonstrated approximately 80% overall response rates, supporting continued advancement of its lead program. Full Read / Communicated Disclaimer https://www.ztradez.net/mdcx

0 · Reply

BullTradeFinder Jun. 4 at 7:58 PM

$MDCX Move over .42 is a big spot. Holding 9 and 21 EMA on daily currently and looking good here for upside. Communicated-Disclaimer https://stockresearchtoday.com/mdcx/

0 · Reply

StockTrader2727 Jun. 4 at 7:54 PM

$MDCX people are missing this one

1 · Reply

The_Titan_Traders Jun. 4 at 3:33 PM

$MDCX Micro-cap biotech with a potentially disruptive skin cancer treatment platform and multiple clinical catalysts ahead. • Strong early clinical data has increased confidence in the lead program’s commercial potential and future regulatory progress. • Advancing toward additional FDA discussions and development milestones that could significantly increase visibility. • Multiple pipeline opportunities provide upside beyond a single asset. • With a small valuation and limited float, positive clinical or regulatory news could drive an outsized move higher. • High-risk, high-reward biotech setup where successful execution could lead to a substantial re-rating. COMMUNICATED-DISCLAIMER: https://stockresearchtoday.com/mdcx/

1 · Reply

JTE_Theta Jun. 4 at 2:28 PM

🚨 $MDCX - $22M non dilutive financing secured ! MDCX is a clinical stage biotech developing SkinJect, a patented microneedle patch that delivers chemotherapy directly to skin cancer lesions as a potential non invasive alternative to surgery. Why investors are paying attention: • SkinJect Phase 2 trial fully enrolled • Positive dose response trends in the lead cohort✅ • Phase 1 delivered complete responses with no dose limiting toxicities • Teverelix advancing in prostate cancer & acute urinary retention • FDA cleared Phase 2b study ✅ • Targeting a $6B combined market opportunity 🤖AI driven clinical development partnership 📈Multiple clinical & regulatory catalysts ahead Small cap biotech + multiple shots on goal + upcoming catalysts = one to watch ! CommunicatedDisclaimer:https://stockresearchtoday.com/mdcx/

0 · Reply

TheRealShortSqueezy Jun. 4 at 1:34 PM

$MDCX : Tiny $18M Market Cap Targeting Multi Billion Dollar Markets!🚨 Medicus Pharma is quietly building a biotech pipeline focused on massive unmet markets in skin cancer and prostate/urology treatments through its proprietary SkinJect and Teverelix programs. Highlights: 🔥 Estimated cash runway now 24+ months 🔥 Positive Phase 2 SkinJect data showed registrational-grade clearance rates 🔥 FDA-cleared advancement for Teverelix Phase 2b study 🔥 Filed Orphan Drug application for SkinJect in Gorlin Syndrome Upcoming Catalysts: ✔️ More SkinJect clinical data ✔️ FDA/regulatory milestones ✔️ Potential partnerships/licensing deals ✔️ Teverelix Phase 2b progression Despite having a market cap of only around $18M, MDCX is pursuing potential multi billion dollar opportunities in markets projected to exceed $12B combined, including skin cancer, which impacts more than 5 million Americans each year. Communicated Disclaimer: http://stockresearchtoday.com/mdcx/ Sector peers: $CERO $MCRB $TCON $ABEO

0 · Reply

harrijakey Jun. 4 at 11:18 AM

$MDCX

0 · Reply

Market Cap	18.86M
Revenue (ttm)	0.00
Net Income (ttm)	-35.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	950,900
Avg Vol	4,471,474
Day's Range	N/A - N/A
Shares Out	56.66M
Stochastic %K	36%
Beta	0.14
Analysts	Strong Sell
Price Target	$5.67